For years, Tempus operated in mystery—its website sparse on details while headlines announced massive funding and high-profile partnerships. The claim? AI-enabled solutions for personalized healthcare. Intrigued, I sought answers. In this episode, Kate Sasser, PhD, Chief Scientific Officer at Tempus, shared insights into how the company uses AI to analyze unstructured clinical data to develop patient-derived organoid models for therapeutic refinement. Most exciting is their vision of an interconnected “lab-in-a-loop” system—a cycle of real-world data, biological modeling, and AI analysis.

Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.